Strides Arcolab Ltd (STAR.BO)
892.50INR
24 May 2013
Rs6.85 (+0.77%)
Rs885.65
Rs879.65
Rs905.00
Rs877.40
204,650
135,359
Rs1,224.90
Rs660.00
STAR.BO
About
Overall
| Beta: | 1.29 |
| Market Cap (Mil.): | Rs52,768.53 |
| Shares Outstanding (Mil.): | 59.05 |
| Dividend: | 2.00 |
| Yield (%): | 0.22 |
Financials
| STAR.BO | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 6.07 | 34.04 | 34.29 |
| EPS (TTM): | 147.14 | -- | -- |
| ROI: | 31.23 | 19.04 | 18.43 |
| ROE: | 49.81 | 19.78 | 19.30 |
Strides Arcolab unit, Pfenex in biosimilars JV
MUMBAI - Agila Biotech, a unit of Indian drugmaker Strides Arcolab , and U.S.-based Pfenex Inc will develop and commercialise six biosimilars for global markets through a joint venture, the two companies said in a statement.
Strides Arcolab unit, Pfenex in biosimilars JV
MUMBAI - Agila Biotech, a unit of Indian drugmaker Strides Arcolab , and U.S.-based Pfenex Inc will develop and commercialise six biosimilars for global markets through a joint venture, the two companies said in a statement.
India's Strides Arcolab unit, Pfenex in biosimilars JV
MUMBAI, April 17 - Agila Biotech, a unit of Indian drugmaker Strides Arcolab, and U.S.-based Pfenex Inc will develop and commercialise six biosimilars for global markets through a joint venture, the two companies said in a statement.
UPDATE 1-India's Strides Arcolab shares sink on dividend worries
(Adds analyst comments, updates share movement) MUMBAI, Feb 28 - Shares in Indian drugmaker Strides Arcolab plummeted as much as 10.6 percent on Thursday, wiping out early gains following its sale of a unit to Mylan Inc for $1.6 billion, as investors were unhappy with Strides' dividend payout, traders said. The shares had initially gained as much as 13.2 percent. The company posted a 10.5 percent fall in net profit for the October-December quarter and declared a 20 percent
Mylan to buy injectable drugs unit of Strides for $1.6 billion
REUTERS - Generic drugmaker Mylan Inc said it will buy a unit of Strides Arcolab Ltd for $1.6 billion to expand its presence in the fast-growing injectable drugs market.
Strides Arcolab shares sink on dividend worries
MUMBAI - Shares in drugmaker Strides Arcolab plummeted about 10 percent on Thursday, wiping out early gains following its sale of a unit to Mylan for $1.6 billion, as investors were unhappy with Strides' dividend payout, traders said.
India's Strides Arcolab shares sink on dividend worries
MUMBAI, Feb 28 - Shares in Indian drugmaker Strides Arcolab plummeted about 10 percent on Thursday, wiping out early gains following its sale of a unit to Mylan for $1.6 billion, as investors were unhappy with Strides' dividend payout, traders said. The shares had initially gained as much as 13.2 percent. The company declared a 20 percent dividend, or 2 rupees per share, for 2012. Strides' injectables unit Agila Specialties generated $700 million in sales and an operating
Mylan to buy injectable drugs unit of Strides for $1.6 billion
REUTERS - Generic drugmaker Mylan Inc said it would buy the injectable drugs unit of Strides Arcolab Ltd for $1.6 billion to expand its presence in the fast-growing generic injectables market.
Mylan to buy injectable drugs unit of India's Strides for $1.6 billion
- Generic drugmaker Mylan Inc said it would buy the injectable drugs unit of India's Strides Arcolab Ltd for $1.6 billion to expand its presence in the fast-growing generic injectables market.
UPDATE 1-Mylan to buy injectable drugs unit of India's Strides for $1.6 bln
Feb 27 - Generic drugmaker Mylan Inc said it would buy the injectable drugs unit of India's Strides Arcolab Ltd for $1.6 billion to expand its presence in the fast-growing generic injectables market.
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
